J&J CEO sends a clear message on the obesity drug boom
Johnson & Johnson (JNJ) just told Wall Street it will sit out the most lucrative drug race of the decade. The decision came straight from the top, at a public event in Washington, on June 16, and it surprised investors who assumed a large drugmaker like J&J would want a piece of the ...
J&J CEO sends a clear message on the obesity drug boom
Overview
Johnson & Johnson (JNJ) just told Wall Street it will sit out the most lucrative drug race of the decade.
The decision came straight from the top, at a public event in Washington, on June 16, and it surprised investors who assumed a large drugmaker like J&J would want a piece of the "weight-loss gold rush."
Instead, CEO Joaquin Duato drew a hard line, stating that J&J is pointing its cash somewhere else entirely.
J&J's stock is trading near record highs, and this decision shows how the company plans to keep growing as sales of its older drugs decline.
Johnson & Johnson is skipping the GLP-1 obesity boom on purpose
Speaking with Carlyle Group cofounder David Rubenstein at the Economic Club of Washington, D.C., Duato said Johnson & Johnson will not enter the obesity drug market, according to Investing.com.
We are not going to be in the GLP-1 area
GLP-1 drugs are the injectable and pill treatments, initially built for diabetes, that curb appetite and have driven historic weight loss for millions of patients.
Duato is satisfied letting Eli Lilly and Novo Nordisk keep that crown.
He pointed to cancer and brain disease as the places where J&J can make a bigger difference and where it already has a head start.
Thinking about Duato's statement, it seems the company is just picking an area of strength to focus on rather than running from concerns about the obesity-drug industry.
J&J would rather lead a market it can own rather than fight for scraps in one that two rivals already control.
What J&J's cancer bet means for the stock
The goal Duato set is blunt: become the No. 1 cancer drug company by 2030.
J&J is backing that with money, not talk.
It closed a $3.05 billion cash deal for Halda Therapeutics, adding an oral prostate-cancer therapy, according to a J&J press release, then agreed to buy Firefly Bio for another $1 billion.
The back-to-back deals show a company reshaping itself around oncology.
More Pharma Stocks:
- Johnson & Johnson bets $1 billion on hard-to-treat cancer
- Eli Lilly's hottest drugs face a quiet new threat
- Goldman Sachs doubles down on Novo stock target after key event
The engine today is multiple myeloma, a cancer of the plasma cells in bone marrow. That franchise brought in roughly $4 billion in the first quarter of 2026, and Duato has set a $50 billion oncology sales target for 2030.
Details
The pivot answers a problem. J&J's immune drug Stelara is losing sales to cheaper copies, and Morgan Stanley, which lifted its price target to $283, sees newer drugs filling that gap.
How the obesity market J&J is avoiding stacks up
What makes the call striking: J&J is passing on enormous numbers.
The five biggest GLP-1 drugs from Lilly and Novo Nordisk are projected to pull in about $470 billion in cumulative revenue through 2030, PharmaVoice reported, citing nonprofit I-MAK.
Goldman Sachs expects the global weight-loss market alone to be worth roughly $95 billion by 2030, according to Drug Discovery and Development.
Related: J&J drops key cancer trial results as Wall Street eyes stock
So why walk away? Lilly and Novo got there first and locked it down, leaving J&J a late, expensive entrant.
The ripple effects reach far beyond pharma, too.
J.P. Morgan estimates GLP-1 drugs could cut annual food and beverage industry revenue by $30 billion to $55 billion by the early 2030s as users eat less.
J&J's perspective is that cancer offers cleaner, more defensible growth than a market that is already crowded and sliding toward price wars.
What still needs to go right for J&J's oncology bet
There are three things investors should watch:
- Darzalex protection: Darzalex, J&J's best-selling cancer drug, loses key patent protection later this decade, so newer drugs have to replace those sales.
- Pipeline approvals: Cancer assets from Halda and Firefly are early-stage and still need regulators to sign off before they sell.
- The $50 billion math: The chances of J&J hitting its 2030 target lean heavily on myeloma, which means trial wins have to keep coming.
For now, the market likes the company's discipline.
JNJ trades around $239, up about 15% year to date and within reach of its 52-week high of $251.71, Yahoo Finance data shows. It carries a market value near $576 billion, a price-to-earnings ratio of about 28, and a 2.2% dividend yield.
First-quarter revenue rose nearly 10% from a year earlier to about $24 billion, and the company beat on both earnings and sales while raising its full-year outlook.
The takeaway for investors is simple:
J&J is betting that owning the cancer drug market is better than stiff competition in obesity, and the stock's steady climb suggests Wall Street is willing to give that thesis time to play out.
For patient investors, the company's dividend payout offers a cushion before its stock begins to price in the cancer bet.
Related: Eli Lilly scores a first in major pharma milestone
Source
Originally published at www.thestreet.com.
